The AbbVie JUVMO FDA approval Parkinson's October 2026 milestone brings a brand-new treatment option to millions of Americans living with Parkinson's disease. The FDA has approved JUVMO (tavapadon) tablets — a once-daily pill that works through a different brain pathway than most existing Parkinson's drugs. And it wasn't the only October approval making headlines: the FDA also cleared the first-ever prescription treatment designed specifically for the negative symptoms of schizophrenia. Here's what both approvals mean for patients.
AbbVie JUVMO FDA Approval Parkinson's October 2026: What Is Tavapadon?
JUVMO is the brand name for tavapadon, developed by AbbVie for adults with Parkinson's disease. Unlike many existing treatments, it is taken once daily and targets the brain's D1/D5 dopamine receptors — a different mechanism from older dopamine agonists. It can be used with or without levodopa, the longtime standard of Parkinson's therapy. Full background on the approval is available at Grafa's US news desk.
Clinical Trial Results: TEMPO-1 and TEMPO-3
The AbbVie JUVMO FDA approval Parkinson's October 2026 decision was backed by strong trial data:
- TEMPO-1: daily-living scores improved by 1.6 points (5 mg dose) and 1.7 points (15 mg dose) versus 0.9 points for placebo at week 26.
- TEMPO-3: patients gained more "on" time without troublesome involuntary movements — meaning more hours of the day with good symptom control and no bothersome dyskinesia.
- Long-term data: an open-label extension study showed sustained efficacy through 85 weeks, an important signal for a chronic, progressive disease.
Side Effects and Who Should Talk to Their Doctor
No drug is free of side effects, and the trials for this AbbVie JUVMO FDA approval Parkinson's October 2026 headline flagged the common ones: nausea, dizziness, hallucinations, and dyskinesia (especially when taken alongside levodopa). If you or a loved one has Parkinson's, the right next step is a conversation with your neurologist — not a self-prescription. Expect JUVMO to be available to US patients later in October 2026.
For more on recent FDA safety actions, see our coverage of the Gatorade recall October 2026 and our roundup of other new FDA approvals from October 2026.
Also Approved This Month: First Treatment for Negative Schizophrenia Symptoms
On October 5, 2026, the FDA cleared Motivista (CT-155) by Click Therapeutics — a prescription digital therapeutic, and the first FDA-authorized treatment specifically for the negative symptoms of schizophrenia: low motivation, social withdrawal, and reduced emotional expression. Details are covered in this FDA clearance report.
It is intended for adults 18 and older whose positive symptoms (like hallucinations) are stable, and it's used as an adjunct to antipsychotic therapy — not a replacement for it. For the nearly 3 million Americans living with schizophrenia, negative symptoms are among the hardest parts of the illness to treat, and until now no therapy was specifically authorized for them.
Why October 2026 Is a Big Month for Brain-Health Medicine
Taken together, these two approvals show how fast neurological and psychiatric treatment is evolving. Tavapadon gives Parkinson's patients a once-daily option with a novel receptor target and durable benefits; Motivista opens an entirely new category — software-based medicine — for schizophrenia's most treatment-resistant symptoms.
The Bottom Line
The AbbVie JUVMO FDA approval Parkinson's October 2026 gives patients and caregivers a meaningful new choice — once-daily dosing, a fresh mechanism of action, and proven gains in daily function. Meanwhile, Motivista's clearance marks the first dedicated treatment for negative schizophrenia symptoms. Both are worth discussing with a doctor if they apply to you or someone you love. And as always with new medicines: exciting science is no substitute for professional medical advice.



